Enochian Biosciences, Inc. (ENOB): Price and Financial Metrics


Enochian Biosciences, Inc. (ENOB): $1.08

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENOB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENOB Stock Price Chart Interactive Chart >

Price chart for ENOB

ENOB Price/Volume Stats

Current price $1.08 52-week high $9.23
Prev. close $1.08 52-week low $0.95
Day low $1.07 Volume 46,100
Day high $1.10 Avg. volume 42,422
50-day MA $1.34 Dividend yield N/A
200-day MA $2.85 Market Cap 57.19M

Enochian Biosciences, Inc. (ENOB) Company Bio


Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.


ENOB Latest News Stream


Event/Time News Detail
Loading, please wait...

ENOB Latest Social Stream


Loading social stream, please wait...

View Full ENOB Social Stream

Latest ENOB News From Around the Web

Below are the latest news stories about ENOCHIAN BIOSCIENCES INC that investors may wish to consider to help them evaluate ENOB as an investment opportunity.

Enochian gets Nasdaq notice for delaying (NASDAQ:ENOB)

Enochian BioSciences (ENOB) said Wednesday it received a notice from Nasdaq stating that the company has not yet filed its Form 10-Q for the period ended September 30, 2022, making…

Seeking Alpha | November 30, 2022

Enochian BioSciences, Inc.: Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("…

Finanz Nachrichten | November 30, 2022

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the

Yahoo | November 30, 2022

Enochian BioSciences Forges Ahead With Focused Approach, Promising Future

LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world’s deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center.

GlobeNewswire | October 24, 2022

Enochian BioSciences, Inc.: Enochian BioSciences Forges Ahead With Focused Approach, Promising Future

LOS ANGELES, Oct. 24, 2022its oncology platform was awarded a U.S. patent and has produced promising early resultsin studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also a…

Finanz Nachrichten | October 24, 2022

Read More 'ENOB' Stories Here

ENOB Price Returns

1-mo -6.09%
3-mo -49.06%
6-mo -53.04%
1-year -75.57%
3-year -76.77%
5-year -75.73%
YTD 4.85%
2022 -85.87%
2021 147.12%
2020 -41.24%
2019 -28.29%
2018 47.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6866 seconds.